Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
A polypeptide for use in medicine is provided. The polypeptide is administered simultaneously, separately or sequentially with an immune checkpoint inhibitor. The polypeptide comprises at least one polypeptide comprising a region of at least 12 amino acids of a self-antigen or a sequence having at least 80% identity to the region. The polypeptide is less than 100 amino acids in length.
1. A method of treatment of cancer in a patient, comprising the steps of:
i) inhibiting an immune checkpoint by administering at least one immune checkpoint inhibitor, wherein the at least one immune checkpoint inhibitor is selected from the group consisting of an anti-CTLA-4 antibody or an antigen-binding fragment thereof, an anti-PD-1 antibody or an antigen-binding fragment thereof and an anti-PD-L1 antibody or an antigen-binding fragment thereof, and wherein the at least one immune checkpoint inhibitor down-regulates or blocks the immune checkpoint; and
ii) simultaneously, separately or sequentially administering: a cocktail of polypeptides comprising:
a) a polypeptide consisting of a sequence of SEQ ID NO. 1 or a fragment thereof comprising at least 12 amino acids;
b) a polypeptide consisting of a sequence of SEQ ID NO. 2 or a fragment thereof comprising at least 12 amino acids; and
c) a polypeptide consisting of a sequence of SEQ ID NO. 3 or a fragment thereof comprising at least 12 amino acids,
wherein the method produces a synergistic effect in the treatment of cancer in the patient.
2. The method according to claim 1 , wherein the synergistic effect comprises an improved clinical outcome in the patient.
3. The method according to claim 2 , wherein the improved clinical outcome is one or more of an improved overall survival and/or an improved effect on tumour size or on the extent of tumour in the body as compared to that obtained with a method in which only an immune checkpoint is inhibited or only the cocktail of polypeptides is administered.
4. The method according to claim 1 , wherein steps i) and ii) are performed within 4 months of each other.
5. The method according to claim 1 , wherein the anti-CTLA-4 antibody is selected from the group consisting of ipilimumab and tremelimumab.
6. The method according to claim 1 , wherein the anti-PD-1 antibody is selected from the group consisting of nivolumab and pembrolizumab.
7. The method according to claim 1 , wherein the anti-PD-L1 antibody is selected from the group consisting of MPDL3280A, MEDI4736, and BMS-936559.
8. The method according to claim 1 , wherein the fragment of SEQ ID NO. 1 comprises at least 14 amino acids or at least 20 amino acids, and/or the fragment of SEQ ID NO. 2 comprises at least 14 amino acids and/or the fragment of SEQ ID NO. 3 comprises at least 14 amino acids.
9. The method according to claim 1 , wherein the cocktail of polypeptides comprises a polypeptide consisting of the sequence of SEQ ID NO. 1, a polypeptide consisting of the sequence of SEQ ID NO. 2 and a polypeptide consisting of the sequence of SEQ ID NO. 3.
10. The method according to claim 1 , wherein step i) comprises the step of administering a first and a second immune checkpoint inhibitor.
11. The method according to claim 10 , wherein the first immune checkpoint inhibitor is an anti-CTLA-4 antibody or an antigen-binding fragment thereof and wherein the second immune checkpoint inhibitor is an anti-PD-1 antibody or an antigen-binding fragment thereof.
12. The method according to claim 11 , wherein the anti-CTLA-4 antibody is ipilimumab and the anti-PD-1 antibody is nivolumab.
13. The method according to claim 1 , wherein step i) and/or ii) is performed simultaneously, separately or sequentially with the administration of a further therapeutic ingredient to the patient.
14. The method according to claim 1 , wherein step ii) is performed simultaneously, separately or sequentially with the administration of an adjuvant and wherein the adjuvant is granulocyte-macrophage colony-stimulating factor (GM-CSF).
15. The method according to claim 1 , wherein a polypeptide in the cocktail of polypeptides is linked to a further substance.
16. The method according to claim 1 , wherein the cancer is one or more selected from the group consisting of melanoma, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, glioblastoma, colon cancer and head and neck cancer.
17. The method according to claim 16 , wherein the melanoma is unresectable or metastatic melanoma, and/or wherein the lung cancer is non-small cell lung cancer, and/or wherein the prostate cancer is metastatic prostate cancer.
18. A method of vaccination for cancer in a patient, comprising the steps of:
i) inhibiting an immune checkpoint by administering at least one immune checkpoint inhibitor, wherein the at least one immune checkpoint inhibitor is selected from the group consisting of an anti-CTLA-4 antibody or an antigen-binding fragment thereof, an anti-PD-1 antibody or an antigen-binding fragment thereof and an anti-PD-L1 antibody or an antigen-binding fragment thereof, and wherein the at least one immune checkpoint inhibitor down-regulates or blocks the immune checkpoint; and
ii) simultaneously, separately or sequentially administering: a cocktail of polypeptides comprising:
a) a polypeptide consisting of a sequence of SEQ ID NO. 1 or a fragment thereof comprising at least 12 amino acids;
b) a polypeptide consisting of a sequence of SEQ ID NO. 2 or a fragment thereof comprising at least 12 amino acids; and
c) a polypeptide consisting of a sequence of SEQ ID NO. 3 or a fragment thereof comprising at least 12 amino acids,
wherein the method produces a synergistic effect in the vaccination for cancer in the patient.
19. The method according to claim 18 , wherein steps i) and ii) are performed within 4 months of each other.
20. The method according to claim 18 , wherein the anti-CTLA-4 antibody is selected from the group consisting of ipilimumab and tremelimumab.
21. The method according to claim 18 , wherein the anti-PD-1 antibody is selected from the group consisting of nivolumab and pembrolizumab.
22. The method according to claim 18 , wherein the anti-PD-L1 antibody is selected from the group consisting of MPDL3280A, MEDI4736, and BMS-936559.
23. The method according to claim 18 , wherein the fragment of SEQ ID NO. 1 comprises at least 14 amino acids or at least 20 amino acids, and/or the fragment of SEQ ID NO. 2 comprises at least 14 amino acids and/or the fragment of SEQ ID NO. 3 comprises at least 14 amino acids.
24. The method according to claim 18 , wherein the cocktail of polypeptides comprises a polypeptide consisting of the sequence of SEQ ID NO. 1, a polypeptide consisting of the sequence of SEQ ID NO. 2 and a polypeptide consisting of the sequence of SEQ ID NO. 3.
25. The method according to claim 18 , wherein step i) comprises the step of administering a first and a second immune checkpoint inhibitor.
26. The method according to claim 25 , wherein the first immune checkpoint inhibitor is an anti-CTLA-4 antibody or an antigen-binding fragment thereof and wherein the second immune checkpoint inhibitor is an anti-PD-1 antibody or an antigen-binding fragment thereof.
27. The method according to claim 26 , wherein the anti-CTLA-4 antibody is ipilimumab and the anti-PD-1 antibody is nivolumab.
28. The method according to claim 18 , wherein step i) and/or ii) is performed simultaneously, separately or sequentially with the administration of a further therapeutic ingredient to the patient.
29. The method according to claim 18 , wherein step ii) is performed simultaneously, separately or sequentially with the administration of an adjuvant and wherein the adjuvant is granulocyte-macrophage colony-stimulating factor (GM-CSF).
30. The method according to claim 18 , wherein a polypeptide in the cocktail of polypeptides is linked to a further substance.
31. The method according to claim 18 , wherein the cancer is one or more selected from the group consisting of melanoma, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, glioblastoma, colon cancer and head and neck cancer.
32. The method according to claim 31 , wherein the melanoma is unresectable or metastatic melanoma, and/or wherein the lung cancer is non-small cell lung cancer, and/or wherein the prostate cancer is metastatic prostate cancer.